Adenosine Kinase: An Epigenetic Modulator and Drug Target
Journal of Inherited Metabolic Disease · 2025-05 · 48 (3)
DOI: 10.1002/jimd.70033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 20.05.2025. Verfasst von Uchenna Peter-Okaka und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Rutgers New Jersey Medical School and Robert Wood Johnson Barnabas Health, New Brunswick, New Jersey, USA. Hauptthemen laut MEDLINE: Adenosine Kinase, Epigenesis, Genetic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Defense, NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Adenosine kinase (ADK, EC: 2.7.1.20) is an evolutionarily ancient ribokinase, which acts as a metabolic regulator by transferring a phosphoryl group to adenosine to form AMP. The enzyme is of interest as a therapeutic target because its inhibition is one of the most effective means to raise the levels of adenosine and hence adenosine receptor activation. For these reasons, ADK has received significant attention in drug discovery efforts in the early 2000s for indications such as epilepsy, chronic pain, and inflammation; however, the report of adverse events regarding cardiovascular and hepatic function as well as instances of microhemorrhage in the brain of preclinical models prevented further development efforts. Recent findings emphasize the importance of compartmentalization of the adenosine system reflected by two distinct isoforms of the enzyme, ADK‐S and ADK‐L, expressed in the cytoplasm and the cell nucleus, respectively. Newly identified adenosine receptor independent functions of adenosine as a regulator of biochemical transmethylation reactions, which include DNA and histone methylation, identify ADK‐L as a distinct therapeutic target for the regulation of the nuclear methylome. This newly recognized role of ADK‐L as an epigenetic regulator points toward the potential disease‐modifying properties of the next generation of ADK inhibitors. Continued efforts to develop therapeutic strategies to separate nuclear from extracellular functions of adenosine would enable the development of targeted therapeutics with reduced adverse event potential. This review will summarize recent advances in the discovery of novel ADK inhibitors and discuss their potential therapeutic use in conditions ranging from epilepsy to cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Rutgers New Jersey Medical School and Robert Wood Johnson Barnabas Health, New Brunswick, New Jersey, USA.
- Department of Neurosurgery, Robert Wood Johnson and New Jersey Medical Schools, Rutgers Health, Piscataway, New Jersey, USA.
- Brain Health Institute, Rutgers University, Piscataway, New Jersey, USA.
- Rutgers Health, Rutgers Cancer Institute, New Brunswick, New Jersey, USA.
ORCID-Profile: Detlev Boison
Förderung
- U.S. Department of Defense
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Peter-Okaka, U., & Boison, D. (2025). Adenosine Kinase: An Epigenetic Modulator and Drug Target. Journal of Inherited Metabolic Disease, 48(3). https://doi.org/10.1002/jimd.70033
Vancouver
Peter-Okaka U, Boison D. Adenosine Kinase: An Epigenetic Modulator and Drug Target. Journal of Inherited Metabolic Disease. 2025;48(3). doi:10.1002/jimd.70033
BibTeX
@article{PeterOkaka2025,
author = {Peter-Okaka, Uchenna and Boison, Detlev},
title = {Adenosine Kinase: An Epigenetic Modulator and Drug Target},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
volume = {48},
number = {3},
doi = {10.1002/jimd.70033}
}
EUVIMED